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Beyond the short-term eﬀects on fertility, there is increasing evidence that obesity or the consumption of an inappropriate diet
by the mother during pregnancy adversely aﬀects the long-term health of her oﬀspring. PPAR and RXR isotypes are widely ex-
pressed in reproductive tissues and in the developing fetus. Through their interactions with fatty acids, they may mediate adaptive
responses to the changes in the maternal diet. In the maturing follicle, PPAR-γ has an important role in the granulosa cells that
surround the maturing oocyte. After fertilisation, PPAR-γ and PPAR-β/δ are essential regulators of placentation and the subse-
quent development of key metabolic tissues such as skeletal muscle and adipose cells. Activation of PPAR-γ and PPAR-β/δ during
fetal development has the potential to modify the growth and development of these tissues. PPAR-α is expressed at low levels in the
fetal liver, however, this expression may be important, as changes in the methylation of DNA in its promoter region are reported to
take place during this period of development. This epigenetic modiﬁcation then programmes subsequent expression. These ﬁnd-
ings suggest that two separate PPAR-dependent mechanisms may be involved in the fetal adaptations to the maternal diet, one,
mediated by PPAR-γ and PPAR-β/δ, regulating cell growth and diﬀerentiation; and another adapting long-term lipid metabolism
via epigenetic changes in PPAR-α to optimise postnatal survival.
Copyright © 2008 William D. Rees et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Human diets in the developed world have changed dramat-
ically during the last century. An increase in the consump-
tion of fat, coupled with a fall in physical activity, has led
to unprecedented rates of obesity in Western populations.
However, the complications associated with these changes in
lifestyle extend beyond the present generation and threaten
the next one. There is an overwhelming body of evidence
showing that the diet and body composition of the mother
modiﬁes the risk of the oﬀspring developing cardiovascular
andmetabolicdiseaseslaterinlife[1].Increasedbodyweight
and decreased physical activity are also associated with ovu-
latory dysfunction and reduced fertility [2, 3]. As the pri-
mary regulators of lipid metabolism at the cellular level, the
peroxisome proliferator-activated receptor (PPAR) isotypes
help to maintain metabolic homeostasis when the energy or
lipid composition of the diet changes. The PPARs are widely
expressed in the reproductive tissues and in the developing
fetus, where by analogy with their function in adult tissues,
they may mediate adaptations to the nutrient supply during
reproduction.Recentstudiesofthemechanismsofmetabolic
programming have begun to shed light on the involvement
of the PPARs in the fetal origins of health and disease [4–6].
In this review, we will consider the possible roles of PPAR
isotypes and the related retinoid X receptor isotypes (RXR)
in the developmental adaptations that occur in response to
ﬂuctuations in the maternal diet.
2. THE ROLE OF LIPID METABOLISM IN
THE FETAL ORIGINS OF DISEASE
Much of the evidence from human and animal studies sug-
gests that inappropriate energy metabolism during preg-
nancy has an adverse eﬀect on fetal development and is an
importantfactorinmetabolicprogramming.Inhumanpop-
ulations, birth weight data is frequently used as a surro-
gate measure of fetal growth and hence the nutrient supply.2 PPAR Research
Several studies have shown that there is a strong relation-
ship between weight at birth and the risk of impaired glucose
tolerance in adult life [7] and that there is a U-shaped rela-
tionship between birth weight and obesity in adult life [8].
Rapid catch-up growth in infancy following a period of fetal
growth restriction carries the highest risk of central obesity
in adulthood, particularly in babies that are thin at birth and
small for gestational age. Importantly it is thinness at birth
and not birth weight itself that explains the relationship be-
tween low birth weight and the long-term metabolic compli-
cations, suggesting that changes in the development of adi-
posity during fetal life is a critical factor [9]. At the other end
of the spectrum, there is a positive association between birth
weight and body mass index at age 20, suggesting that ele-
vated birth weight is also associated with an increase in adi-
posity [10]. Mothers who are diabetic or develop serious ges-
tational diabetes give birth to babies that are large for gesta-
tional age. These oﬀspring of hyperglycaemic mothers have a
muchhigherriskofdevelopingmetabolicsyndromeinchild-
hood, demonstrating a link between maternal blood glucose
levels and perturbed metabolism in the oﬀspring [11]. Thus,
it appears that there are two diﬀerent mechanisms underly-
ing the development of glucose intolerance and obesity in
adult life: one at the higher end of the birth weight spectrum,
associated with maternal hyperglycemia, and another at the
lower end associated with the development of adipose tissue
[8].
Animal models for fetal programming also implicate
lipidandcarbohydratemetabolismintheprogrammingpro-
cess. Pertinent to this discussion of the role of PPARs in de-
velopment are studies in which the maternal diet modiﬁes
lipid metabolism. Feeding rats a high-fat diet during ges-
tation programmes glucose intolerance, pancreatic beta-cell
dysfunction, and increases the body weight of their oﬀspring
[12, 13]. Other metabolic perturbations in gestation such as
modestproteinrestriction,orirondeﬁciencyalsoleadtoper-
sistent changes in the oﬀspring. These also are linked indi-
rectly to changes in lipid metabolism in the dam. In the case
of protein restriction, triglyceride concentrations in the ma-
ternalplasmaareincreasedinanimalsfedthelow-proteinra-
tions and this is associated with changes in the expression of
PPAR-αin theoﬀspring [14].Thisincreasein plasmatriglyc-
erides can be modulated by the fatty acid composition of the
diet [15], an intervention which also modiﬁes the eﬀects of
protein deﬁciency on glucose tolerance in the oﬀspring [16].
Micronutrients in the maternal diet are also important and
thereisevidencethattheireﬀectsarealsomediatedindirectly
through changes in lipid metabolism. For example, iron de-
ﬁciency reduces triglyceride concentrations in the liver of the
Fe-restrictedfetusesbyapproximately25%withcorrespond-
ing changes in the expression of SREBP-1c and its down-
stream genes [17]. There are also reports that vitamin A de-
ﬁciency during gestation is associated with impaired glucose
tolerance in adult life [18].
Both human and animal studies suggest that there are a
number of critical windows in development where changes
in the maternal diet can inﬂuence the long-term outcome of
the oﬀspring. These span the entire reproductive cycle from
the preconception period when the germ cells mature right
through gestation and into the lactation period (Figure 1).
3. PPARs DURING PRECONCEPTION DEVELOPMENT
Evolutionary forces favour animals able to regulate their fer-
tility in response to the availability of nutrients in the envi-
ronment. Metabolic status at the start of the reproductive cy-
cle before conception is a good guide to subsequent success.
Whilst these controls have developed to deal with famine,
inappropriate responses to dietary excess or imbalance are
more of concern in the modern world. Because of the links
between body composition and infertility, there is consider-
able interest in the mechanisms by which nutrient sensors,
such as the PPARs, regulate the maturation of the oocyte.
All of the PPAR isotypes are expressed in the rat ovary.
PPAR-γ is found in the granulosa cells that surround and
support the maturing oocyte. PPAR-α and PPAR-β/δ are
present at lower levels in the thecal and stromal cells [19].
The low levels of the PPAR-α and PPAR-β/δ isotypes sug-
gest that they play a role in basal ovarian function whereas
the higher levels of the PPAR-γ isotype imply a more spe-
ciﬁc function in the granulosa cell [20]. However, PPAR-γ is
not essential, as mice with a targeted deletion of the gene in
granulosa cells are able to reproduce successfully, albeit with
reduced fertility, related to a reduced implantation rate [21].
Instead PPAR-γ appears to be a negative regulator of follicu-
lar growth and diﬀerentiation. The viability of rat granulosa
cells is reduced when they are treated with a speciﬁc PPAR-γ
agonist, suggesting that PPAR-γ activation suppresses follicle
development [22]. Recent studies also suggest that follicular
functions are sensitive to dietary factors in vivo. Trans fatty
acids increase the risk of ovulatory infertility when they re-
place the unsaturated fats that are commonly found in veg-
etable oils [23]. Since these fatty acids are able to activate
PPAR-γ, the data suggest that it may be an important trans-
ducer.
Eﬀectsonovulation,mediatedbyPPAR-γ inconjunction
with RXR isotypes, may go beyond eﬀects on fertility. Early
embryonicdevelopmentisdependentonstoresofmaternally
derived factors passed from the granulosa cells to the oocyte
during maturation. If these stores are depleted due to poor
granulosa cell function, there may be an eﬀect on the imme-
diate postnatal development following fertilisation. A small
change in growth during this early stage may be the start of
a chain of events leading to long-lasting eﬀects, such as ele-
vated blood pressure in the oﬀspring [24].
The PPARs are also expressed in the testis [20]w h e r e
lipid metabolism and especially the β-oxidation of fatty acids
are important for testicular function. Peroxisome prolifera-
tors, such as phthalates are known testicular toxicants. They
interfere with the transcriptional activity of RAR-α in Sertoli
cells by increasing the nuclear localisation of PPAR-α and in-
creasing its transcriptional activity [25]. The extensive accu-
mulation of neutral lipids in the testis has been observed in a
number of mouse models in which key genes such as RXR-β
have been deleted [26]. These ﬁnding suggest that the regu-
lation of lipid metabolism by PPAR and RXR may be impor-
tant in the regulation of male fertility. Unlike ovulation, theWilliam D. Rees et al. 3
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Figure 1:PPARisotypeexpressionandprogrammingduringthereproductivecycle.ThePPAR-β/δ andPPAR-γ isotypesregulatethegrowth
ofkeyorgansandmanagethedevelopmentofadiposetissueduringfetaldevelopment.Duringthelaterstagesoffetaldevelopmentepigenetic
programming of PPAR-α (represented by the grey section of the arrow) programmes long-term postnatal regulation of energy metabolism.
impactofhigh-fatdietsandobesityonthefunctionofPPARs
during spermatogenesis is a relatively unexplored area. It is
interesting to note that there has been a marked decrease in
male fertility concomitant with the developing obesity epi-
demic suggesting that this is an area in need of further study.
4. PPARs DURING IMPLANTATION
AND PLACENTATION
Following fertilisation there is a rapid diﬀerentiation of the
early embryo into specialised cell types. This is the ﬁrst stage
of cellulardiﬀerentiation whenthe tissues within the embryo
begin to develop specialised metabolic functions. With this
evolving complexity there is a requirement for mechanisms
to maintain metabolic homeostasis between the diﬀerent tis-
sues. As the interface with the maternal circulation, the ex-
traembryonic endoderm and then the placenta perform vital
functions in regulating the nutrient supply to the developing
tissues. The growth of the fetus is dependent on appropriate
placental development, as a small placenta will restrict the
availability of nutrients.
The PPAR isotypes play an important role in regulating
the implantation of the embryo and the development of the
placenta [27]. The mRNAs for RXR-α,R X R - β and PPAR-γ as
well as the RXR-β and PPAR-γ proteins, have been detected
in the trophectoderm and inner cell mass cells of intact and
hatched blastocysts [28]. In mice, nutrients are transported
through this extraembryonic endoderm prior to implanta-
tion. In cultures of trophoblast cells, activation of PPAR-γ
or RXR with selective agonists enhances the uptake of free
fatty acids and increases the accumulation of neutral lipids
by increasing the expression of the FATP-4 transporter lo-
cated in the brush-border membrane [29]. Thus, at this very
early stage of development before the placenta is fully devel-
oped, the availability of substrates can modify the use of fatty
acids by the embryo. At present, little is known about the im-
pact of high-fat diets or obesity in this period and it remains
to be seen if an increased utilisation of fatty acids at this stage
has any long-term impact on the fetus.
The PPAR-β/δ and PPAR-γ isotypes also regulate fatty
acid metabolism after the embryo has implanted and the
placenta has developed. Fatty acids are used by the devel-
oping fetus for energy metabolism, membrane biosynthesis,
and synthesis of signalling molecules. The PPAR-β/δ mRNA
is ubiquitously expressed throughout the placenta including
the labyrinth, the spongiotrophoblast, and the giant cells.
Homozygous disruption of PPAR-β/δ results in the death of
the majority of fetuses between days 9.5 and 10.5 of gesta-
tion. Pathological changes are mainly found in the giant cell
layer of the placenta. The time of death corresponds to the
period when PPAR-β/δ controls the diﬀerentiation and ac-
cumulation of lipid droplets in these cells [30]. In contrast,4 PPAR Research
PPAR-γ isrequiredforthedevelopmentofthelabyrinthlayer
of the placenta. The placentae of PPAR-γ null mice have im-
paired vascularisation [31] and fewer lipid droplets in the
labyrinthinetrophoblasts[32],resultinginembryoniclethal-
ity at about day 9.5 of gestation. Conversely, the activation
of PPAR-γ by the administration of speciﬁc agonists in vivo
reduces the thickness of the spongiotrophoblast layer, modi-
ﬁes the labyrinthine vasculature, and enhances fatty acid up-
take and the expression of fatty acid transport proteins [33].
However, information on the action of nutritional factors is
sparse. Metabolic perturbations such as those produced by
experimental diabetes increase the expression of PPAR-γ and
proteins that are regulated by it such as vascular endothelial
growth factor [34]. These ﬁndings suggest that the PPAR-γ
pathway might be involved in the impairment of placental
development induced by high-glucose conditions. They also
suggest that high-fat diets or obesity may also modify PPAR-
γ signalling in the placenta due to high concentrations of
lipids in the maternal circulation.
5. THE DEVELOPMENT OF ORGAN SYSTEMS
Further metabolic specialisation occurs within the fetus as
the diﬀerent organ systems develop. In the adult, the PPAR
isotypes and isoforms play central roles in the metabolic
interplay that occurs between the diﬀerent organs. In the
adult, adipose tissue, skeletal muscle, the liver, and pancre-
aticbeta-cellsareallinvolvedintheregulationofglucoseand
lipid metabolism. The maternal diet has the potential to pro-
gramme subsequent metabolism by modifying the develop-
ment of these tissues during fetal development.
The association between thinness at birth and adult dis-
ease has been linked to the development of adipose tissue
in utero, a process that involves both PPAR-γ and PPAR-
β/δ. Animal studies suggest that the maternal diet does
not inﬂuence either the proliferation or diﬀerentiation of
preadipocyte cells in vitro [35]. Once preadipocytes have
been isolated from the oﬀspring, they proliferate and diﬀer-
entiate normally, suggesting that regulation must occur dur-
ing fetal development. Many diﬀerent transcription factors
are involved in the commitment of mesenchymal stem cells
to the adipocyte lineage [36]. Amongst these are PPAR-β/δ,
which is expressed during the preadipose stages, and PPAR-
γ, which is expressed as part of the mature adipocyte pheno-
type. Targeted deletions of the PPAR-β/δ and PPAR-γ genes
in mice have demonstrated that both genes are essential for
adipogenesis. The small numbers of PPAR-β/δ null mice that
do not succumb to placental failure have an extremely lean
phenotype, typiﬁed by a 2.5-fold reduction of abdominal
f a tm a s sc o m p a r e dw i t hc o n t r o ll i t t e r m a t e s[ 37]. Similarly,
PPAR-γ null mice, rescued by forming chimeras in which
the placenta is formed from wild-type cells, die soon after
birth because they are devoid of adipose tissue [32]. PPAR-
γ-mediated signalling regulates adipogenesis in the adult by
formingapositivefeedbackloop,sensitivetolong-chain,sat-
urated, and polyunsaturated fatty acids in the diet [38]. It is
probable that this same system is able to regulate the devel-
opment of fetal preadipose cells and adipocytes in situations
where there are elevated levels of fatty acids supplied to the
fetal tissues from either the maternal diet or through the mo-
bilisation of maternal adipose reserves.
Altered muscle development may be an important ele-
ment in prenatal programming of the metabolic syndrome.
Skeletal muscles are a major site of carbohydrate and fatty
acid metabolism and small changes induced during devel-
opment have long-lasting eﬀects. The oﬀspring of rats fed
high-energy diets (cafeteria diet) during gestation and lac-
tation have fewer muscle ﬁbres and more intramuscular fat,
related to an increase in the expression of PPAR-γ mRNA
in the muscle [39]. There is good evidence showing that
both PPAR-β/δ and PPAR-γ regulate the expression of the
genes involved myogenesis. Targeted expression of an acti-
vatedformofPP AR -β/δ intheskeletalmusclesofmicemakes
the animals resistant to obesity by increasing the numbers of
oxidative muscle ﬁbres [40], while the selective ablation of
PPAR-β/δ induces obesity by reducing the oxidative capac-
ity of the muscles [41]. In muscle cell cultures, PPAR-β/δ has
been shown to regulate the expression of genes involved in
fatty acid transport, beta-oxidation, and mitochondrial res-
piration [42]. Muscle speciﬁc ablation of the PPAR-γ gene in
mice also produces animals that are obese and insulin resis-
tant [43]. In contrast to the positive eﬀects of PPAR-β/δ on
myogeneisis, the overexpression of PPAR-γ in myoblast cul-
tureshasbeenshowntoinhibittheformationofmyotubesby
suppressing the expression of muscle-speciﬁc myogenic pro-
teins including myogenin, MyoD, and creatine kinase [44].
As a great deal of myogenesis takes place before birth, both
PPAR-β/δ and PPAR-γ could be important regulators of fe-
tal muscle development in response to lipids in the maternal
diet.
Change in the size of the pancreatic islets due to an in-
crease in beta-cells is an important feature of some animal
models of fetal programming. PPAR-γ mediated signalling
has been implicated in the regulation of beta-cell prolifera-
tion in adults. Mice in which the expression of the PPAR-
γ gene was eliminated in beta-cells were found to have sig-
niﬁcant islet hyperplasia [45]. Paradoxically PPAR-γ agonists
also enhance pancreatic growth [46] and the expression of
key transcriptional activators required for beta-cell diﬀer-
e n t i a t i o ni nc e l lc u l t u r e s[ 47]. The reasons for these diﬀer-
ences are unexplained. There is good evidence showing that
changes in beta-cell expansion during the later stages of fe-
tal development depend on glucocorticoids [48]. Thus, the
role of PPAR-γ in the fetal pancreas remains unclear. How-
ever, the possibility remains that it may be important when
the developing pancreas is exposed to high levels of fat from
maternal obesity or high-fat diets.
The liver is the main site of PPAR-α expression in the
adult, with much lower levels of the PPAR-β/δ and PPAR-γ
isotypes found in this tissue. Homozygous disruption of the
PPAR-α,P P A R - β/δ, and PPAR-γ genes has no eﬀect on the
development of the liver; and the oﬀspring exhibit no appar-
ent abnormalities [49]. However, PPAR-α is expressed in the
fetal liver albeit at much lower levels than in the adult [50];
and as discussed below this fetal expression may be impor-
tant in the programming of postnatal expression.William D. Rees et al. 5
The RXR isotypes also plays a central role in organo-
genesis [51]. Recent studies of the mouse epidermis have
suggested that 9-cis retinoic acid is not the in vivo lig-
and of RXR [52]. The actions of various pharmacological
agents and the observation that keratinocytes do not contain
retinoids suggest that fatty acids are the natural RXR ligand
and that RXR is acting as a lipid sensor. Thus, it is possi-
ble that the same fatty acids are able to activate both part-
ners of a PPAR:RXR heterodimer. If these ﬁndings hold for
PPAR:RXR heterodimers in other tissues then this represents
a clear mechanism by which the availability of fatty acids can
inﬂuence fetal development.
6. THE PROGRAMMING OF PPAR-α EXPRESSION
Persistent alterations to the phenotype of the oﬀspring imply
stable changes in gene expression. Candidate genes for such
eﬀects arise from studies showing altered gene expression in
the oﬀspring of laboratory animals fed restricted diets. There
is accumulating evidence that there are long-term changes
in the stable expression of PPAR-α [14] and of genes regu-
lated by it, including acetyl-CoA carboxylase and fatty acid
synthase [16, 53]. A change in the expression of these genes
is associated with impaired lipid homeostasis in the adult.
Recent studies have found evidence for epigenetic changes
in the PPAR-α gene which may account for this program-
ming [4]. Analysis of genomic DNA using methylation spe-
ciﬁc restriction enzymes suggests that the methylation of the
exon 1 promoter was approximately 20% lower in the oﬀ-
spring of rats fed a low-protein diet in gestation. At the same
time, there was a 10-fold increase in the mRNA for PPAR-
α. These changes were speciﬁc for PPAR-α as there was no
change in the methylation status of the PPAR-γ gene. Simi-
lar epigenetic changes induced during fetal development and
persistingintoadultlifewithlong-lastingeﬀectsonthephys-
iological mechanisms have been demonstrated with the glu-
cocorticoid receptor [54].
Nutrient sensitive transcriptional activators, such as the
PPAR-α, are able to determine local chromatin structure
through interactions with coactivator proteins. Indeed, these
interactions are an essential component of the mechanism of
transcriptional activation [55]. Even when there is no ligand
present, PPARs form heterodimers with RXRα which bind
to DNA in association with a number of corepressor pro-
teins. Binding of a ligand to a PPAR dissociates the corepres-
sor protein complex, releasing the PPAR:RXR heterodimer
which then sequentially associates with various transcrip-
tional coactivator proteins. This protein complex modiﬁes
histone andchromatinstructure,making theDNAaccessible
fortranscriptionwhileatthesametimerecruitingRNApoly-
merase II and activating the transcriptional machinery. The
proteins involved in the coactivator complex include PGC-1
histone acetyl transferases, histone deacetylases and methyl
transferases [55]. At present, there are no reports of coac-
tivators with transcriptional functions speciﬁc to the PPAR
subfamily. Individual coactivators are shared by many tran-
scription factors and are involved in numerous signalling
pathways [56, 57]. For example, the nuclear receptor coac-
tivator PBP (PPAR-binding protein) functions as a coacti-
vator for other members of the nuclear receptor family. A
targeted deletion of the PBP gene in hepatocytes reduces
the association of other unrelated cofactors, especially the
cyclic-AMP responsive element binding protein and thyroid
hormone receptor-associated proteins to the PPAR-α depen-
dent mouse enoyl-CoA hydratase/L-3-hydroxyacyl-CoA de-
hydrogenase gene promoter [58]. Within the nuclear recep-
tor coactivation complex there are some proteins, which do
not directly bind to nuclear receptors but are present in the
complex due to their binding to other coactivators. Amongst
these are proteins that can methylate histones. It has also
been suggested that changes in the recruitment of the Dnmt-
1 methyl transferase to the promoter during development
may be responsible forthe modiﬁcation ofDNA methylation
at the glucocorticoid receptor [59].
Thus, interactions between PPAR-α and its ligands in the
liver during fetal development may be important in adapting
chromatin structure, and hence long-term expression, to the
nutrient supply likely to be encountered by the fetus in post-
natal life. Because these modiﬁcations occur before PPAR-α
is required for metabolic regulation, this may be a molecu-
lar mechanism which establishes the sensitivity of the devel-
oping tissue to nutrient signals. These modiﬁcations to the
metabolic phenotype may be beneﬁcial when nutrients are
limited, as it provides a mechanism that will adapt the re-
sponse of the oﬀspring to a poor diet in the postnatal en-
vironment. Equally, when the diet is high in fat and carbo-
hydrates, hepatic metabolism will be well adapted to direct
excess fat towards storage in adipose tissue and prevent some
of the adverse eﬀects of lipotoxicity.
7. CONCLUDING REMARKS
PPAR and RXR isotypes have an essential role in the home-
ostatic mechanisms that maintain energy metabolism in the
adult. There is now increasing evidence that they ensure that
the metabolic tissues of the fetus develop in a controlled way
during gestation. It appears that there may be two diﬀerent
PPAR-mediated mechanisms involved in the fetal origins of
health and disease. One is mediated via PPAR-γ,w h i c hr e g -
ulates the growth of key organs and manages the develop-
ment of adipose tissue during fetal development. The other
is mediated via PPAR-α in which epigenetic control prepro-
grammes long-term regulation of energy metabolism.
Bioactive factors such as lipids, carbohydrates, amino
acids, as well as lipid-derived hormones crossing the placen-
tal barrier may disrupt this careful balance in metabolism.
Critically, regulatory systems that have evolved to deal with
famine are poorly suited to deal with nutrient excess. High
levels of lipid, either from the diet or derived from exces-
sive maternal stores may overwhelm the protective mech-
anisms oﬀered by the PPAR receptors. Once inappropriate
control points are established, then metabolic balance will be
disturbed for the remainder of life. Insulin resistance pro-
g r a m m e da tf e t a ls t a g e sw i l lb e c o m em o r ep r o n o u n c e dw i t h
age, ultimately leading to the development of metabolic dis-
ease.6 PPAR Research
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